The schema newly classified 15.4% of persons without airflow obstruction as having COPD by minor diagnostic category, Surya P ...

Representative Jefferson Shreve recently sold up to $50K in Regeneron stock, then made it rain on Chipotle and tech. The ...

call that signals the jockeys to mount their horses.The hats that Biles wore during the weekend were made in Louisville by The Hat Girls.Now, Biles’ hats will go up for auction to benefit Kosair ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against Billionaire Mario Gabelli’s other large-cap stock picks with huge upside potential.

Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price objective reduced by Truist Financial from $975.00 to $940.00 in a research note released on Wednesday,Benzinga reports.

In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other stocks. Discussing two decades of Mad Money, Jim Cramer took a moment ...

Yuzvendra Chahal's sensational hat-trick dismantled Chennai Super Kings, while Shreyas Iyer's brilliant 71 propelled Punjab Kings to a four-wicket victory, ending CSK's playoff hopes. Curran's ...

It was Yuzvendra Chahal's second hat-trick in IPL, and he became the third player to claim it multiple times in the tournament. Yuzvendra Chahal claimed a hat-trick against CSK on Wednesday.( ...

Yuzvendra Chahal produced a performance for the ages in the IPL 2025 as he became the first bowler this edition to pick a hat-trick. The Punjab Kings spinner finished with figures of 4/32 against ...

Shares of Regeneron Pharmaceuticals Inc. REGN advanced 5.25% to $598.76 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX ...

Regeneron Pharmaceuticals Inc. REGN shares are trading higher on Wednesday, recovering after a drop on Tuesday that followed the release of weaker-than-expected first quarter 2025 financial results.

Regeneron has leveraged its monoclonal antibody research and development platform to become one of the few biotechs to emerge as a profitable commercial operation and establish a narrow moat.